Tetomilast

替托司特

Report date: 2022/09/07 15:30:04
NME

Base Information

Drug NameTetomilast
Drug Alias Nametetomilast谢敏tetomilastum替米司特特托米特 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodieterase 4 inhibitors
TargetsPhosphodieterase 4
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhejiang Otsuka Pharmaceutical Co LtdOtsuka Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesOtsuka Pharmaceutical Co Ltd
Inactive CompaniesOtsuka Pharmaceutical Development & Commercialization IncZhejiang Otsuka Pharmaceutical Co Ltd
Active IndicationsPulmonary Disease, Chronic Obstructive
Inactive IndicationsCrohn DiseaseColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A